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Background: People with kidney failure are often deficient in zinc and selenium, but little is known about the
optimal way to correct such deficiency.
Methods: We did a double-blind randomized trial evaluating the effects of zinc (Zn), selenium (Se) and vitamin E
added to the standard oral renal vitamin supplement (B and C vitamins) among hemodialysis patients in Alberta,
Canada. We evaluated the effect of two daily doses of the new supplement (medium dose: 50 mg Zn, 75 mcg Se,
250 IU vitamin E; low dose: 25 mg Zn, 50 mcg Se, 250 IU vitamin E) compared to the standard supplement on
blood concentrations of Se and Zn at 90 days (primary outcome) and 180 days (secondary outcome) as well as
safety outcomes.
Results: We enrolled 150 participants. The proportion of participants with low zinc status (blood level <815 ug/L)
did not differ between the control group and the two intervention groups at 90 days (control 23.9% vs combined
intervention groups 23.9%, P > 0.99) or 180 days (18.6% vs 28.2%, P = 0.24). The proportion with low selenium status
(blood level <121 ug/L) was similar for controls and the combined intervention groups at 90 days (32.6 vs 19.6%,
P = 0.09) and 180 days (34.9% vs 23.5%, P = 0.17). There were no significant differences in the risk of adverse events
between the groups.
Conclusions: Supplementation with low or medium doses of zinc and selenium did not correct low zinc or
selenium status in hemodialysis patients. Future studies should consider higher doses of zinc (≥75 mg/d) and
selenium (≥100 mcg/d) with the standard supplement.
Trial registration: Registered with ClinicalTrials.gov (NCT01473914)
Keywords: Hemodialysis, Selenium, ZincBackground
People with severe kidney disease follow a restricted diet
aimed at reducing intake of sodium, potassium and
phosphate [1], which may lead to nutritional deficiency.
Although the potential for malnutrition in people with
kidney disease is well recognized, blood levels of most
vitamins and trace elements are rarely measured. In-
stead, many North Americans with severe kidney disease
are routinely prescribed a “renal vitamin” which contains
a mixture of B and C vitamins.* Correspondence: tonelli.admin@ucalgary.ca
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unless otherwise stated.Recent evidence indicates that people with kidney failure
are often deficient in zinc and selenium [2]. Potential bene-
fits of zinc supplementation relevant to dialysis patients in-
clude improved immune function, taste sensitivity (perhaps
reducing dietary sodium intake), and appetite [3]. Potential
benefits of selenium supplementation include reduced risk
of vascular disease and infection [4]. Although vitamin E
supplements reduced serious cardiovascular morbidity in a
randomized controlled trial of people with kidney failure
[5], this treatment is not routinely used in dialysis patients.
Thus supplementation of zinc, selenium, and vitamin E
may benefit patients with kidney failure. Since patients with
kidney failure already take many medications, it is logical to
combine any new nutritional supplements with the existingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and selenium may be toxic in large doses or when accumu-
lated over time. Therefore, the optimal dose of zinc and sel-
enium is unknown for people with kidney failure, in whom
renal excretion of these elements is impaired or absent.
We did a randomized trial in hemodialysis patients
evaluating a novel nutritional supplement consisting of
zinc, selenium and vitamin E added to the contents of
the standard renal supplement (B and C vitamins). We
compared two doses of the new supplement with the stand-
ard supplement with respect to serum concentrations in
hemodialysis patients over 180 days of supplementation.
Methods
Participants
Participants were recruited from the Northern and
Southern Alberta Renal Programs (from November 2012
to June 2013, from dialysis wards in Edmonton, Calgary
and Red Deer, Alberta. Written informed consent was
obtained. The Universities of Alberta and Calgary re-
search ethics boards approved the study. This trial is re-
ported according to the CONSORT guidelines [6].
Adults (≥18 y) stable on thrice weekly hemodialysis for
3 to 36 months receiving Replavite (WN Pharmaceuti-
cals Ltd; Coquitlam, BC, Canada) or an equivalent renal
vitamin at baseline were eligible for inclusion. Patients
who were allergic to or intolerant of zinc, selenium, vita-
min E, Replavite or corn starch were excluded from the
trial. We excluded pregnant patients or patients plan-
ning a pregnancy, scheduled kidney transplantation or
gastrointestinal surgery, anticipating a switch in dialysis
modality, or estimated life expectancy <6 months. We
also excluded patients with an ostomy/short gut syn-
drome, participants in another clinical trial, patients with
head and neck cancer diagnosed in the past 5 years
(given theoretical risks associated with selenium supple-
mentation in this population), and those taking zinc,
selenium, or vitamin E supplementation at baseline.
Interventions
Participants were randomly assigned to 1 of 3 interven-
tions: the standard renal vitamin formulation (biotin 300
mcg, folic acid 1 mg, niacinamide 20 mg, thiamine
1.5 mg, cyanocobalamin 6 mcg, riboflavin 1.7 mg, pyri-
doxine 10 mg, ascorbic acid 100 mg; control), the stand-
ard formulation compounded with vitamin E (250 IU)
and low doses of zinc (25 mg) and selenium (50 mcg),
or the standard formulation compounded with vitamin E
(250 IU) and medium doses of zinc (50 mg) and selen-
ium (75 mcg) (Additional file 1: Table S1). The appear-
ance (size, colour, and capsule) and taste of the 3
vitamin compounds were exactly the same. Doses were
selected to minimize the risk of toxicity in the setting of
kidney failure and incorporated information on themaximum recommended dietary intake for healthy
people (zinc: 40 mg/d [7]; selenium 400 mcg/d [8]) as
well as prior studies in this population.
Zinc 25 mg and selenium 50 mcg daily (low dose for-
mulation) are standard doses for supplementation in the
general population, and similar or higher doses have
been used in previous studies of hemodialysis patients
without evidence of toxicity [9-11]. The higher doses of
zinc 50 mg and selenium 75 mcg daily contained in the
medium dose formulation may be more suitable for dia-
lysis populations. We did not study high dose supple-
mentation with zinc or selenium (doses ≥75 mg or ≥100
mcg respectively).
Outcomes
Predialysis serum zinc and selenium concentrations were
measured at 90 and 180 days (or at early withdrawal)
following the baseline visit. The primary outcome was
the proportion of participants in the combined medium
and low dose groups who have low zinc status at 90 days
(<815 ug/L; low zinc status) [12], compared to the stand-
ard vitamin group. The proportions of participants with
low zinc status at 180 days, and with low selenium status
(<121 ug/L) [12] at 90 and 180 days were also compared
between groups as secondary outcomes.
Other secondary outcomes included serum levels of
zinc and selenium, inter-dialytic weight gain and salt
sensitivity (recognition and detection thresholds using
SALSAVE [Advantech Toyo Co; Tokyo, Japan] test
strips). We also collected data on serious adverse events
(death, life-threatening illness, hospitalization, persistent
and significant disability) and non-serious adverse events
potentially related to the trial interventions (self-reported
tremor, colour and texture of fingernails, frequent vomiting
[>3 per week], severe neutropenia [WBC <3.5x109/L],
severe anemia [Hb <60 g/L].) Because high (usually 150–
250 mg/d) doses of zinc can interfere with copper metabol-
ism [13], we also compared the proportion of patients in
each group with low copper status [<1061 ug/L] [12] at the
end of the study.
Laboratory methods
Zinc, selenium and copper were measured using the
Agilent 8800 ICP mass spectrometer with helium and
oxygen as the reaction gases. The calibration range for
Cu and Zn is 0.1-100ug/L, while that for Se is 0.01-10
mcg/L. In each batch of samples, calibrators and 2
sources of CRMs (Certified Reference Materials) were
run prior to sample injections. The CRMs used in this
analysis were Seronorm Trace Metals Serum Control
Level 1 and 2 and Clinchek Trace Metals Serum Control
Level 1 and 2. The CRMs were re-injected after every 10
samples and the results were accepted within 20% range
of the target values. Observed CV% (within run-between
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enium respectively. For each sample batch, some sam-
ples were randomly picked as duplicates. The difference
in percentage between duplicates was calculated and the
results were accepted if the difference was less than 15%.
If this criterion was not met, the sample was repeated in
a different run.Covariates
We collected data on the following demographic vari-
ables: age, gender, and ethnicity (white or otherwise).
Obesity (body mass index ≥30 kg/m2) and current smok-
ing status were recorded as well as the following baseline
comorbidities: cancer, coronary artery disease, diabetes,
heart failure, hypertension, peripheral vascular disease,
seizure disorder and stroke.Trial design
This was a randomized, double-blind, active-control, 3-
group, parallel trial that was registered with Clinical-
Trials.gov (NCT01473914). Participants were asked to
take the intervention orally, once per day after dialysis
or the same time of day as they would generally finish
dialysis, for 180 days following the baseline visit. The
intervention assignments were equally allocated between
groups using randomly-generated permuted blocks of 6
and 9. The serially numbered identical bottles were pre-
filled with the trial vitamin compounds using lists of
intervention assignments, one generated for each renal
program, and labelled with the trial name, the site name,
and the site and participant number. The randomization
lists were kept in a locked cabinet by the statistician who
generated the lists. Participants, study coordinators and
study investigators with the exception of the study statis-
tician were kept unaware of the intervention assign-
ments. Lab personnel who were involved in outcome
ascertainment (serum concentrations) were also unaware
of the therapy that participants had received.
Data were collected via participant interviews, chart
reviews and clinical databases at baseline, 30, 90,
180 days (when the trial intervention was stopped), and
30 days following the discontinuation of the trial inter-
vention. Medical history, medication use and demo-
graphics were ascertained at baseline. Pre-dialysis blood
samples were taken by qualified dialysis unit personnel
at day 90 and day 180 and stored in a −80°C freezer at
the Canadian Biosample Repository. The dialysis pre-
scription, pre- and post-dialysis blood pressure and
weight data collection, the salt sensitivity testing, the
trial intervention compliance checked, and the serious
and non-serious adverse event reviews were completed
at each interview. Adverse event reviews were also com-
pleted 30 days following the discontinuation of the trialintervention. All adverse events were reviewed by the
site investigators within 24 hours.
A sample size of 150 participants (approximately 50
participants per group) was chosen to provide 80%
power (with a 5% type 1 error rate and a 30% loss to
follow-up) to detect a relative reduction in low zinc sta-
tus of 33% (or an absolute reduction from 90% to 60%)
between the combined medium and low dose groups
and the standard vitamin group. No interim analyses
were planned due to the short duration of the trial.
Statistical analyses
All analyses were completed in Stata/MP 13.0 (www.stata.
com). The primary analysis followed an intention-to-treat
approach. In sensitivity analyses, missing outcome data
were imputed using a last-value carried forward approach.
Per protocol results were also generated. Baseline descrip-
tive statistics were reported as counts and percentages, or
medians and inter-quartile ranges, as appropriate.
For continuous outcome data, we used mixed regres-
sion models where participant was modelled as a ran-
dom intercept, and intervention, time, the interaction
between intervention and time, renal program (NARP,
SARP) and baseline value were modelled as fixed effects.
For inter-dialytic weight gain where there was a max-
imum of 9 time points (3 dialysis runs at 30, 90 and
180 days on intervention), residuals within the partici-
pant were modelled using an exponential covariance-
variance matrix. The exponential covariance-variance
matrix allows for non-equidistances between consecutive
time points; the matrix has two parameters: a shared
variance and a correlation which would be raised to the
difference between any two time points. For dichotom-
ous outcomes (e.g., low element status) we used simple
χ2 tests. In sensitivity analyses, we used generalized lin-
ear mixed models (with a logistic link and the binomial
family) and adjusted for intervention, time, their inter-
action, renal program and the baseline low element sta-
tus. Means with 95% confidence intervals were reported,
or counts and percentages, where appropriate. The
means were adjusted for dialysis unit location and the




Six hundred and four hemodialysis patients were screened
for inclusion in the trial; 454 were excluded (Figure 1).
Characteristics of the 150 patients who were enrolled
and randomized are shown in Table 1. Study flow is
shown in Figure 1. The dataset was locked on March
21, 2014.
The median age of participants was 62 years; 74% were
male, and most were white (79%). Median BMI was
Figure 1 Participant flow diagram. All participants who received at least one dose of the trial intervention were included in the intention-to-treat
primary analysis (51 in the medium dose group, 47 in the low dose group, and 49 in the standard dose group). *Participants may have more than
one reason for ineligibility.
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12% had co-morbid diabetes. Thirty-seven percent had
low zinc status at baseline. The demographic and clinical
characteristics of the treatment groups were generally
comparable at baseline, although more control partici-
pants had low serum copper (53% vs 42% or 49%) and low
selenium status (28% vs 15% or 19%). Overall adherence
(assessed by counting the number of remaining capsules)
was 83%.Zinc
The proportion of participants with low zinc status de-
clined during follow-up for all three treatment groups
(Figure 2). The proportion of participants with low zinc
status did not differ between the control group and the
two intervention groups combined at 90 days (23.9% vs
23.9%, P > 0.99) or 180 days (control 18.6% vs combined
intervention groups 28.2%, P = 0.24). Results were simi-
lar after adjustment for low zinc status at baseline (P =




N 52 47 51
Age, y 63 (59,67) 60 (57,64) 58 (54,62)
Male 39 (75) 35 (74.5) 37 (72.5)
Caucasian/white 41 (78.8) 36 (76.6) 42 (82.4)
BMI, kg/m2 29 (27,30) 31 (29,34) 27 (25,29)
Smoker 4 (7.8) 8 (17) 13 (25.5)
Primary cause of ESRD
Diabetes 22 (42.3) 26 (55.3) 19 (37.3)
Glomerulonephritis 10 (19.2) 9 (19.1) 7 (13.7)
Hypertension 7 (13.5) 4 (8.5) 8 (15.7)
PCKD 1 (1.9) 1 (2.1) 6 (11.8)
Other 11 (21.2) 7 (14.9) 11 (21.6)
Comorbidities
Cancer 8 (15.7) 8 (17) 7 (13.7)
CAD 21 (41.2) 16 (34) 15 (29.4)
Diabetes1 9 (17.6) 4 (8.5) 5 (9.8)
Heart failure 12 (23.5) 6 (12.8) 12 (23.5)
Hypertension 41 (80.4) 38 (80.9) 33 (64.7)
PVD 4 (7.8) 2 (4.3) 2 (3.9)
Seizure disorder 2 (3.9) 2 (4.3) 3 (5.9)
Stroke 3 (5.9) 5 (10.6) 3 (5.9)
Salt sensitivity
No recognition 10 (19.6) 9 (19.2) 10 (19.6)
Recognition2 0.8 (0.7,0.9) 0.8 (0.7,0.8) 0.8 (0.7,0.8)









Selenium 139 (135,143) 137 (133,142) 135 (129,141)
Zinc 884 (851,917) 861 (823,898) 911 (867,955)
Low copper status 22 (42.3) 23 (48.9) 27 (52.9)
Low selenium status 8 (15.4) 9 (19.2) 14 (27.5)
Low zinc status 20 (38.5) 20 (42.6) 18 (35.3)
N (%) or mean (95% confidence intervals) where appropriate. Low copper
status <1061 ug/L. Low selenium status <121 ug/L. Low zinc status <815 ug/L.
BMI body mass index, ESRD end-stage renal disease, PCKD poly cystic kidney
disease, CAD coronary artery disease, PVD peripheral vascular disease.
1Those participants with diabetic nephropathy were not included in the
counts for comorbid diabetes.
2In those participant with recognition of a salty taste.
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not significantly differ between the control group and
the combined intervention groups at 90 or 180 days
(932 vs 998 ug/L, P = 0.11; 972 vs 982 ug/L, P = 0.23, re-
spectively). However, serum zinc level was significantlyhigher in participants receiving the medium dose inter-
vention (50 mg/d) vs control at 90 and 180 days (1032
vs 932 ug/L, P = 0.04; 1036 vs 972 ug/L, P = 0.04). Re-
sults were similar for the per-protocol analysis and the
sensitivity analysis using imputed values (data not
shown).
Selenium
The proportion of participants with low selenium status
was similar for controls and the combined intervention
groups at 90 days (32.6 vs 19.6%, P = 0.09) and 180 days
(34.9% vs 23.5%, P = 0.17). Results were similar after adjust-
ment for low selenium status at baseline (P = 0.28, P =
0.67). As compared to controls, mean serum concentration
was significantly higher in the combined intervention group
at 90 days but not 180 days (143 vs 131 ug/L, P < 0.001;
137 vs 135 ug/L, P = 0.07). Mean serum selenium concen-
tration was significantly higher in participants receiving the
medium dose intervention (75 mcg/d) at 90 days (146 vs
131 ug/L, P < 0.001) and at 180 days (139 vs 135 ug/L, P =
0.03). Results were again similar for the per-protocol ana-
lysis and the sensitivity analysis using imputed values (data
not shown).
Salt sensitivity
Compared with controls, the recognition and detection of
salt sensitivity was not significantly different for the com-
bined intervention groups at day 90 or day 180 (recogni-
tion 32.6 vs 40.2%, and sensitivity 25.0 vs 26.1% at day 90;
recognition 34.1 vs 42.7%, and sensitivity 28.1 vs 26.1% at
day 180). Results were significant when controls were
compared with the medium dose treatment group for rec-
ognition at day 90 (32.6 vs 55.3%, P = 0.03) but did not re-
main significant at day 180 (34.1 vs 46.8%, P = 0.22).
Interdialytic weight gain
The weight gain between dialysis treatments was mea-
sured on nine occasions: all three runs during the weeks
of day 30, day 90, and day 180. Mean weight gain was
approximately 2 kg between each timepoint and for each
group (Table 2). There were no significant differences
between groups.
Adverse events
There were no significant differences in the risk of ser-
ious and non-serious adverse events between groups
(Table 3). There were a total of six deaths during the
trial; none in the medium dose intervention group, 4 in
the low dose intervention group and 2 in controls (P for
controls vs treatment groups combined P = 0.65). There
were a total of 29 hospitalizations and the proportion of
participants hospitalized at least once were not signifi-
cantly different between control and treatment recipients




baseline day 90 day 180 baseline day 90 day 180
Figure 2 Zinc and selenium by timepoint. The left panels show the proportion of participants with low zinc status in the upper left panel and
the mean serum zinc concentration of the participants in the lower left panel. The right panels show the proportion of participants with low
selenium status in the upper right panel and the mean serum selenium concentration of the participants in the lower right panel. The lower
panels have black horizontal lines depicting the thresholds of low element status (serum zinc <815 ug/L and serum selenium <121 ug/L). The
solid line represents the control group. The dashed line represents the low dose intervention group and the short-dashed line represents the
medium dose intervention group.
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vs 17.2%)
A total of 17 participants reported non-serious adverse
events such as tremor, changes in the color or texture of
fingernails, vomiting, mild neutropenia, or mild anemia.
The proportion of participants experiencing at least one
of these events was not significantly different between
control and treatment recipients (14.3 and 10.2%, re-
spectively; p = 0.59).
Discussion
Overall, supplementation with zinc and selenium had
only modest effects on serum selenium levels and did
not decrease the proportion of participants with low
levels of either trace element. Results with the medium
dose supplement (50 mg of zinc and 75 mcg of selen-
ium) increased serum levels of zinc and selenium.Supplementation with zinc and selenium did not enhance
salt recognition or sensitivity, although there were non-
significant trends to improvement when the medium dose
supplement was considered. There was no evidence that
supplementation increased the risk of adverse effects.
Most previous studies of zinc supplementation in
hemodialysis patients predominantly used doses of
50 mg/d, which safely increased zinc levels and (in one
study) salt sensitivity [9,10,14]. Other studies used higher
doses, zinc 100 mg/d, apparently without adverse effects
[15,16]. There are fewer studies of selenium supplemen-
tation in dialysis populations, but 200 and 300 mcg/d
were both used in short-term studies of hemodialysis pa-
tients, without an increased risk of adverse events
[11,17,18]. We chose relatively low doses of zinc and sel-
enium because we were concerned about the risk of tox-
icity. However, our results suggest that higher doses of
Table 2 Outcomes at 90 and 180 days
Medium dose Low dose Medium and low dose combined Standard dose P-value
At day 90
Zinc
Low status, % 10 (21.7) 12 (26.1) 22 (23.9) 11 (23.9) <0.99
Concentration, ug/L 1032 (960,1104) 970 (900,1039) 998 (945,1052) 932 (860,1003) 0.11
Selenium
Low status, % 8 (17.4) 10 (21.7) 18 (19.6) 15 (32.6) 0.09
Concentration, ug/L 146 (141,152) 140 (134,146) 143 (139,147) 131 (125,137) <0.001
Inter-dialytic weight gain, kg 1.96 (1.70,2.22) 2.20 (1.94,2.46) 2.08 (1.88,2.28) 2.01 (1.74,2.28) 0.64
Salt sensitivity
Recognition improved 26 (55.3) 11 (24.4) 37 (40.2) 15 (32.6) 0.39
Sensitivity improved 11 (32.4) 7 (20.0) 18 (26.1) 8 (25.0) 0.91
At day 180
Zinc
Low status, % 10 (22.2) 14 (35.0) 24 (28.2) 8 (18.6) 0.24
Concentration, ug/L 1036 (964,1109) 927 (854,1001) 982 (928,1037) 972 (898,1046) 0.23
Selenium
Low status, % 9 (20.0) 11 (27.5) 20 (23.5) 15 (34.9) 0.17
Concentration, ug/L 139 (134,145) 135 (129,141) 137 (133,142) 135 (130,141) 0.07
Inter-dialytic weight gain, kg 1.99 (1.69,2.29) 2.16 (1.85,2.47) 2.17 (1.95,2.40) 1.97 (1.66,2.28) 0.26
Salt sensitivity
Recognition improved 22 (46.8) 16 (38.1) 38 (42.7) 15 (34.1) 0.24
Sensitivity improved 11 (31.4) 7 (20.6) 18 (26.1) 9 (28.1) 0.83
Count (percentage) and adjusted mean (with 95% confidence intervals) where appropriate; values were adjusted for the NARP site and the mean baseline value.
P-values statistically compare the combined dose group to the standard group. Bolded values are significantly different from the standard group. Low selenium
status <121 ug/L. Low zinc status <815 ug/L.
Table 3 Adverse events
Medium dose Low dose Medium and low
dose combined
Standard dose Exact P-value
Non-serious events 7 (13.7) 3 (6.4) 10 (10.2) 7 (14.3) 0.59
Self-reported tremor 0 (0) 1 (2.1) 1 (1.0) 0 (0) <0.99
Color and texture of fingernails 3 (5.9) 1 (2.1) 4 (4.1) 2 (4.1) <0.99
Frequent vomiting 0 (0) 1 (2.1) 1 (1.0) 2 (4.1) 0.26
Severe neutropenia 3 (5.9) 0 (0) 3 (3.1) 3 (6.1) 0.40
Severe anemia 1 (2.0) 0 (0) 1 (1.0) 0 (0) <0.99
Low copper status 23 (50.0) 22 (47.8) 45 (48.9) 27 (58.7) 0.28
Serious events
Death 0 (0) 4 (8.5) 4 (4.1) 2 (3.9) 0.65
Hospitalization1 8 (15.4) 9 (19.2) 17 (17.2) 7 (13.7) 0.79
Hospitalizations 9 12 21 8
Counts (percentages) are reported. P-values statistically compare the combined dose group to the standard group. Bolded values are significantly different from
the standard group. Low copper status <1061 ug/L.
15 participants (3 in the low dose group and 1 in the standard dose group and 1 in the medium dose group) had 2 SAE-specific hospitalizations. In the above
analysis, only 1 hospitalization is counted per participant (rather than per SAE-specific event).
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zinc and selenium status in hemodialysis patients.
Because of a previous RCT [5] suggesting that vitamin
E supplementation prevented cardiovascular events in
hemodialysis patients, we included 250 IU of tocopherol
in the two active treatments. We would have preferred to
use a higher dose of vitamin E, but this was not possible
without an unacceptable increase in capsule size. Unfortu-
nately, we cannot determine whether the lack of benefit of
study drug on cardiovascular outcomes was due to low
statistical power or an inadequate dose of tocopherol – or
because vitamin E supplementation does not prevent car-
diovascular events in hemodialysis populations.
Why did we not observe improved serum concentrations
of zinc or selenium? First, hemodialysis might remove
unbound trace elements such as zinc and selenium from
blood, meaning that higher maintenance doses would be
required. Second, gastrointestinal absorption might be
compromised in the presence of kidney failure, especially in
the setting of nausea and vomiting (which is more common
in dialysis patients than in the general population) [19].
Third, the severe dietary restrictions and frequent anorexia
associated with kidney failure might lead to very low dietary
trace element intake – meaning that unusually high doses
are required to overcome deficiency. Fourth, although there
is no a priori reason that co-administration with vitamins
B, C and E should reduce absorption, it is possible that the
combination therapy we studied somehow reduced bio-
availability of zinc and selenium compared to monotherapy.
Fifth, failure to take the supplements as requested is a
possible explanation for the lower-than-expected effects on
zinc and selenium status. Adherence in our study was 83%
as assessed by capsule count but true adherence may have
been lower. Finally, our study was powered primarily to
detect an effect of treatment for the two supplement groups
combined as compared with control. Our results are
compatible with a small but still potentially beneficial effect
of supplementation with medium dose zinc and selenium
on serum le- vels – and suggest that higher doses warrant
future study.
Our study has important strengths that should be con-
sidered when interpreting its results. First, it was a ran-
domized, double-blind study that was done with minimal
risk of bias. Second, all serum trace element assays were
done using batched samples (to avoid assay drift) at a sin-
gle reference laboratory. The laboratory followed rigorous
quality assurance protocols reducing the potential for
measurement error. However, our study also has some
limitations. First, it was relatively small (N = 150) and used
two active treatment arms, which likely reduced statistical
power for comparisons of treatment vs placebo. Second,
although it is one of the longest studies of trace element
supplementation ever done in a kidney failure population,
a longer study would be required to conclusively assesssafety. In addition to reducing the frequency of low zinc
and/or selenium levels, a future study demonstrating ben-
efits for patient-important outcomes would be required to
inform clinical practice. Third, assessment of zinc and sel-
enium status is complex, and potentially affected by nutri-
tional status as well as shifts between intracellular and
extracellular compartments [20-22]. Although blood levels
are considered acceptable measures of zinc and selenium
status, the precise level that represents biological defi-
ciency is not known for the general population or for dia-
lysis patients. We did not evaluate biomarkers of zinc
status such as serum metallothionein activity or plasma
levels of glutathione peroxidase. Fourth, and most import-
ant, the doses of supplementation used were relatively
conservative, which may have reduced the likelihood of
showing a beneficial effect on trace element status in this
population.Conclusions
In conclusion, we found no convincing evidence that
supplementation with low or medium doses of zinc and
selenium corrected abnormal trace element status in
hemodialysis patients. Future studies of oral trace elem-
ent supplementation should compare higher doses of
zinc (≥75 mg/d) and higher doses of selenium (≥100
mcg/d) with control. If these higher doses are also insuf-
ficient to correct low blood levels of zinc and selenium,
consideration of parenteral supplementation may be
worthwhile.Additional file
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